Dr. Lee, Yu-Ru ’s Lab李育儒 博士 實驗室


The study of my lab responds to multifaceted focus areas, including ubiquitination, cancer signaling, tumor biology, non-coding RNA, CRISPR screening and targeting therapy/immunotherapy, and addresses one of overarching challenges, to develop effective treatments for the most advanced cancers, including triple negative breast cancer, colon, prostate and liver cancer. We will combine multifaceted cutting-edge approaches, including rigorous biochemical, cellular, genetic engineered mouse models (GEMMs), organoid systems and the new high throughput screening platform by integrating a genome-wide platform on both coding and non-coding CRISPR screening system, which allows us for the first time to assess the functions of novel genes at a genome-wide level. By understanding the mechanistic insights and the control of coding genes/non-coding genes in tumorigenesis will not only help us broaden the knowledge of tumor biology in cancer with various origins, but also lay the framework for either coding based- or RNA based-targeting and immunotherapy cancer interventions. Our ultimate goal is to translate all of these into clinics and, hopefully, these works will hold tremendous promise to human patients.


我實驗室的研究主要著重在這幾個領域,包括泛素化、癌症信號傳導,腫瘤生物學、非編碼RNA、CRISPR 高通量篩選和標靶/免疫療法, 以其找到有效治療多種癌症的方法,包括三陰性乳腺癌、結腸癌、前列腺癌和肝癌。我們將利用全基因組的高通量篩選平台來找尋哪些編碼或者非編碼的基因是對於癌症發展的關鍵分子。除此之外,我們也會結合完善的生化、細胞、基因工程小鼠模型(GEMM)以及類器官 (Patient-Derived Tumorids)等多方面嶄新的方法來探討這新基因在癌症發展中所扮演的功能及分子機制。透過這些方法使我們能夠在全基因組水平上評估這些新基因的功能。通過了解這些編碼基因/非編碼基因在腫瘤發展過程中之調控以及功能,不僅將有助於增加我們對癌症發展的認識,而且還將提供基於編碼或基於RNA的標靶/免疫療法的新策略。我們的最終目標是將所有這些研究都轉譯到臨床治療上,以期造福癌症病人。

Dr. Lee, Yu-Ru
李育儒 博士

Assistant Research Fellow

Ph.D., Institute of Molecular Medicine, National Taiwan University College of Medicine;  Instructor in BIDMC, Harvard Medical School;  Post-doc in BIDMC, Harvard Medical School
  • Cancer Genetics
  • Cancer Signaling, Post-translational Modifications, Non-coding RNAs
  • Cancer Biology, Targeted/Immunotherapy

NEWS 最新消息

  1. (Dec 2022) Taiwan Government Scholarship for Studying Abroad

    Jan 01, 2023
  2. (July 2022) Excellent Poster Award

    Jul 13, 2022
  3. Congratulations and welcome!

    Jul 13, 2022
  4. Welcome!

    Jul 13, 2022



WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models
Journal of Clinical Investigation, Dec 15, 2021
Dual DNA and protein tagging of open chromatin unveils dynamics of epigenomic landscapes in leukemia
Nature Methods, Mar 18, 2021
WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition
New England Journal of Medicine, May 28, 2020